Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 0.49 |
| ▸ | HTR6 | P50406 | 4/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15771770 | 0.88 | BRD4 (0.53) | BRD4HTR6L3MBTL1 | |
| SCHEMBL15069587 | 0.84 | BRD4 (0.56) | BRD4 | |
| SCHEMBL20412202 | 0.76 | BRD4 (0.51) | BRD4 | |
| SCHEMBL31590455 | 0.75 | BRD4 (0.58) | BRD4HTR6L3MBTL1KDM4E | |
| SCHEMBL31590015 | 0.74 | BRD4 (0.56) | BRD4HTR6L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL17492683 | 0.74 | BRD4 (0.52) | BRD4HTR6 | |
| SCHEMBL16739024 | 0.74 | BRD4 (0.46) | BRD4 | |
| SCHEMBL17492642 | 0.74 | BRD4 (0.53) | BRD4HTR6L3MBTL1ALDH1A1 | |
| SCHEMBL23647192 | 0.72 | BRD4 (0.51) | BRD4HTR6KDM4EALDH1A1 | |
| SCHEMBL15771835 | 0.72 | BRD4 (0.62) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070756-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2021-03-11 | — | — | US | disclosed |
| US-20200291027-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
| EP-3539962-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-2970330-B1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2019-04-17 | — | — | EP | disclosed |
| US-20180298003-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2018-10-18 | — | — | US | disclosed |
| US-10035800-B2 | Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors | ABBVIE INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20160039821-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC. | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035800-B2 | Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors | BRD1, BRD3, BRD4 | BRD4 3/4885HTR6 1725/4885L3MBTL1 3406/4885 |
| US-20180298003-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | BRD3, BRD4, BRD1 | BRD4 2/4885HTR6 2199/4885L3MBTL1 1497/4885 |
| US-20200291027-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | BRD3, BRD4, BRD1 | BRD4 2/4885HTR6 2199/4885L3MBTL1 1497/4885 |
| US-20210070756-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | BRD3, BRD4, BRD1 | BRD4 2/4885HTR6 2199/4885L3MBTL1 1497/4885 |
| US-20160039821-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | BRD3, BRD4, BRD1 | BRD4 2/4885HTR6 1942/4885L3MBTL1 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.